Testing effectiveness (Phase 2)WithdrawnNCT02662296
What this trial is testing
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Who this might be right for
Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+1 more
Fred Hutchinson Cancer Center